After years of weight loss drug shortages, the FDA is saying there’s now an adequate supply for most medications and they ...

Several weight loss drug stocks are sliding today as pharmaceutical companies battle for dominance in the booming GLP-1 ...

Compounding pharmacies will have to stop producing copycats of tirzepatide, the active ingredient in the blockbuster weight ...

How weight loss drugs actually work, and how big-name prescriptions differ from each other. What investors need to know about ...

Hims & Hers generated $1.5 billion in revenue in 2024, reflecting a 69% year-over-year increase. See why I rate HIMS stock a ...

Hims & Hers Health (NYSE:HIMS) shares were on a massive run, but that momentum hit a wall recently. Since its peak on ...

Roller-coaster healthcare stock Hims & Hers Health (NYSE: HIMS), whose stock got devastated last week by worries that it ...

Hims & Hers Health (HIMS) has disclosed plans to shut down Apostrophe, its acne treatment business. This change is part of ...

Last week, the news on Hims & Hers was all about how a Texas court ruling confirmed the FDA can declare an end to the shortage of tirzepatide-based GLP-1 weight-loss drugs from Eli Lilly (NYSE ...

In an increasingly competitive telehealth weight loss market, thoughtful and transparent branding is critical.

Telehealth personalized care company Hims & Hers shuttered a central part of its dermatology offering, skincare brand Apostrophe, to "simplify" its dermatology offerings and operation | Hims & Hers ...